Philochem is a Swiss subsidiary of the Philogen group (www.philogen.com), acting as discovery center for the group. Philochem’s activities focus on chemical pharmaceutical products and technologies. Read all
Philogen announces publication of best-in-class FAP-targeting small molecule ligand (OncoFAP) in PNAS Study shows impressive tumor uptake of OncoFAP with unprecedented selectivity against...
Read allPhilochem complements the pipeline of Philogen (which focuses on antibody products) with pharmaceutical products based on small organic molecules. Read all
Over the years the Philogen group has developed products and technologies in collaboration with leading pharmaceutical companies, including: